Evidence map›Paper›PMID 42286358›Full record

ArticleNature immunology2026

mRNA-based tuberculosis vaccines BNT164a1 and BNT164b1 are immunogenic, well tolerated and efficacious in rodent models.

Neha Agrawal, Louis S Ates, Stefan A Schille, Anuhar Chaturvedi, Janina Vogt, Natasa Vukovic, Charles L Dulberger, Annette B Vogel, Jan Diekmann, Mustafa Diken and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Neha Agrawal *BioNTech SE, Mainz, Germany.ORCID http://orcid.org/0000-0001-8506-6559
Louis S Ates *BioNTech SE, Mainz, Germany. louis.ates@biontech.de.ORCID http://orcid.org/0000-0002-2953-8010
Stefan A Schille *BioNTech SE, Mainz, Germany.ORCID http://orcid.org/0000-0001-5395-8368
Anuhar ChaturvediBioNTech SE, Mainz, Germany.ORCID http://orcid.org/0000-0002-9597-3010
Janina VogtBioNTech SE, Mainz, Germany.
Natasa VukovicBioNTech SE, Mainz, Germany.ORCID http://orcid.org/0000-0002-9083-2104
Charles L DulbergerBioNTech US, Cambridge, MA, USA.
Annette B VogelBioNTech SE, Mainz, Germany.
Jan DiekmannBioNTech SE, Mainz, Germany.
Mustafa DikenBioNTech SE, Mainz, Germany. mustafa.diken@biontech.de.ORCID http://orcid.org/0009-0005-4391-4042
Uğur ŞahinBioNTech SE, Mainz, Germany.ORCID http://orcid.org/0000-0003-0363-1564

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We designed and preclinically tested two mRNA-lipid-nanoparticle-based vaccine candidates to protect against tuberculosis. BNT164a1 and BNT164b1 encode the same eight Mycobacterium tuberculosis antigens expressed across different infection stages: Ag85A, Hrp1, ESAT-6, RpfD, RpfA, HbhA, M72 and VapB47. BNT164a1 utilizes nucleoside-unmodified mRNA, whereas BNT164b1 utilizes N

Indexed as

Antigens, BacterialMycobacterium tuberculosisRNA, MessengerTuberculosisTuberculosis VaccinesAnimalsAntibodies, BacterialCD8-Positive T-LymphocytesDisease Models, AnimalFemaleHumansMiceMice, Inbred BALB CMice, Inbred C57BLRatsAntibodies, BacterialAntigens, BacterialRNA, MessengerTuberculosis Vaccines

Identifiers

PMID42286358
PMCPMC13414557

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.